Immunotherapy for renal pelvis cancer is gemcitabine monotherapy combined with PD-1 monoclonal antibody local therapy, and the general treatment cycle is 6 months, but the therapeutic effect is still under research. The main treatment modes of renal pelvis cancer are surgery, radiotherapy and chemotherapy. 1. Surgery: For patients with high-grade, large lesions or renal parenchyma invasion of renal pelvis cancer, radical resection, such as nephroureterectomy and cystectomy, is mainly recommended. For renal pelvis cancer with only localized superficial growth, organ-preserving surgery, such as transurethral ureteroscopy or nephrolithotomy, can be adopted. 2. Adjuvant therapy of radiotherapy: radiotherapy can effectively inhibit the spread of tumor cells of renal pelvis cancer, and it is usually used as adjuvant therapy after surgery, such as gemcitabine, etc. It is mainly applicable to the treatment of low-differentiated metastatic renal pelvis cancer. Renal pelvis cancer refers to malignant tumors occurring in the mucosa of renal pelvis or renal calyx, of which the most common is migrating epithelial papilloma. At present, the most important treatment is still surgical resection, and if immunotherapy is to be carried out, immune target detection is needed and the therapeutic effect is not clear for the time being. Patients with renal pelvis cancer can undergo surgery supplemented by radiotherapy or immunotherapy, but the specific treatment plan should be comprehensively decided by the doctor after examination, so as to avoid poor therapeutic effect.